Abstract
Background and Objectives SARS-CoV-2 (COVID-19) continues to mutate, circulate, and adversely impact health and quality of life. While COVID-19 vaccines remain safe and effective, uptake remains low, especially among children, the youngest of whom were not vaccine-eligible until after Omicron and are underrepresented in published research. This study estimated vaccine effectiveness (VE) among under-5-year-olds.
Methods We used Virginia Department of Health surveillance data from June 2022 through October 2022 to conduct a test negative case-control study. We estimated VE derived from odds ratios (ORs) of reported infections using logistic regression among children aged 6-months to 5-years.
Results Using the earliest positive (cases) or negative (controls) post-vaccine-eligible test results, the VE associated with two doses of a COVID-19 vaccine was 78% (95% CI=45%, 93%; p=0.004) in unadjusted analyses and 70% (95% CI=25%, 91%, p=0.023) when adjusting for age, sex, prior testing behavior, and prior reported infections. The adjusted VE was 74% (95% CI=28%, 94%; p=0.025) among those with no prior positives reported and 45% (95% CI=-302%, 97%; p=0.569) among those with a prior positive reported.
Conclusions These results show that even though the vaccine was not closely matched to the dominant variants circulating during the time period analyzed, it was effective at reducing the risk of reported infections. This study adds to the body of knowledge on pediatric COVID-19 VE in an underrepresented age-group and in a rural region, illustrates the utility of surveillance data for evaluation, and can inform vaccine decisions to improve vaccine uptake for young children.
What’s Known on This Subject SARS-CoV-2 (COVID-19) continues to mutate, circulate, and adversely impact health and quality of life. While research continues to show that COVID-19 vaccines remain safe and effective, uptake remains low, especially among young children who were not vaccine-eligible until after Omicron.
What This Study Adds Children under-5 are underrepresented in published COVID-19 vaccine effectiveness research. This test negative case-control study estimates VE in this age-group following vaccine approval after the 2022 Omicron wave, using surveillance data from the Virginian Department of Health in Southwest Virginia.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards (IRBs) of Virginia Tech (IRB#: 20-852) and the Virginia Department of Health (IRB#: 70046). The study was determined to be public health surveillance as defined in the US Department of Health and Human Services, Title 45 Code of Federal Regulations, 46 Protection of Human Subjects (45 CFR 46.102[l]), and thus informed consent was not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures: The authors have no conflicts of interest relevant to this article to disclose.
Funding/Support: This project was supported by an Interdisciplinary Team-Building Pilot Grant from the Virginia Tech Center for Emerging, Zoonotic, and Arthropod-borne Pathogens for 2022-23, a Go Virginia Economic Resilience and Recovery Grant (20-GOVA-ERR-02A and 20-GOVA-ERR-02D), the Department of General Services of the Commonwealth of Virginia (DGS-201020-UVT), and funds from Virginia Tech, the Fralin Biomedical Research Institute at Virginia Tech Carilion, and the Fralin Life Sciences Institute.
Role of Funder/Sponsor: The funders had no role in the design and conduct of this study.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- AAP
- American Academy of Pediatrics
- ACIP
- Advisory Committee on Immunization Practices
- AIC
- Akaike information criterion
- CDC
- Centers for Disease Control and Prevention
- CI
- Confidence interval
- COVID-19
- Coronavirus disease 2019
- FDA
- Food and Drug Administration
- IRB
- Institutional Review Boards
- OR
- Odds ratio
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SWVA
- Southwest Virginia
- VDH
- Virginia Department of Health
- VE
- Vaccine effectiveness
- VEDSS
- Virginia Electronic Disease Surveillance System
- VIIS
- Virginia Immunization Information System
Funder Information Declared
